Stockscreener 앱 받기
0.9158
0.58%
0.0053
전일 마감가:
$0.9105
열려 있는:
$0.93
하루 거래량:
137.76K
Relative Volume:
0.02
시가총액:
$11.97M
수익:
-
순이익/손실:
$-7.51M
주가수익비율:
-0.6938
EPS:
-1.32
순현금흐름:
$-8.02M
1주 성능:
-13.60%
1개월 성능:
-29.01%
6개월 성능:
+29.53%
1년 성능:
-29.55%
1일 변동 폭
$0.88
$0.95
1주일 범위
$0.88
$1.065
52주 변동 폭
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
명칭
Hoth Therapeutics Inc
전화
(646)756-2997
주소
590 MADISON AVENUE, NEW YORK, NY
HOTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.9158 | 11.97M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.76 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.00 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
618.50 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.64 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
268.56 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-10-15 | 개시 | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc 주식(HOTH)의 최신 뉴스
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - MSN
Hoth Therapeutics (NASDAQ:HOTH) Given Buy Rating at D. Boral Capital - Defense World
Hoth Therapeutics to Present at the LD Micro Main Event (XII) - ACCESS Newswire
What to expect from HOTH’s earnings report this quarter? - US Post News
Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic - Contract Pharma
HOTH's Cancer Breakthrough: Strategic Alliance Accelerates Novel HT-KIT Therapeutic Research - StockTitan
Hoth Therapeutics expands at-the-market offering by $5 million - Investing.com Australia
Research Analysts Set Expectations for HOTH FY2024 Earnings - Defense World
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at HC Wainwright - Defense World
Hoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsNew York, NY – January 24, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced today that it has successfully regained compliance with the minimum bid price requirement s - Defense World
Financial Contrast: Hoth Therapeutics (NASDAQ:HOTH) vs. Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Hoth Therapeutics expands cancer drug patent portfolio - MSN
Hoth Therapeutics Breaks New Ground! Nasdaq Compliance Achieved! - Mi Valle
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements - PR Newswire
Hoth Therapeutics expands cancer drug patent portfolio By Investing.com - Investing.com Australia
Hoth Therapeutics Acquires New Patent Applications - Contract Pharma
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications - PR Newswire
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 - PR Newswire
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More - MSN
Shares Of This Micro Cap More Than Doubled Today - MSN
3 Penny Stocks to Watch Now, 1/9/25 - TipRanks
Hoth Therapeutics maintains strong cash position, no offering plans By Investing.com - Investing.com Nigeria
Hoth Therapeutics Shares Recover; Company Has No Plans for Offering - MarketWatch
Hoth Therapeutics maintains strong cash position, no offering plans - Investing.com
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries - PR Newswire
S&P 500 E-Mini (ESM23) Quote - The Globe and Mail
Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s Excited - Asianet Newsable
Dow Jones Transportations Average (DOWT) QuotePress Release - The Globe and Mail
Dow Jones Global (DOWG) QuotePress Release - The Globe and Mail
Hoth reports 100% success in cancer skin toxicity trial By Investing.com - Investing.com South Africa
Hoth Therapeutics up over 218% on dermatology breakthrough for cancer patients - Mugglehead
Hoth Therapeutics stock hits 52-week high at $1.73 By Investing.com - Investing.com Australia
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
PHLX Euro FX (XDE) QuotePress Release - The Globe and Mail
Hoth Therapeutics Inc (HOTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.65%
자본화:
|
볼륨(24시간):